Journal of Pediatric Neurosciences · 2017 · 47 citations · 19 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyNeonatologyNeuropharmacologyInfant PharmacotherapyNeonatal Drug TherapyNeonatal NeurologyNeonatal PharmacologyNeonatal PharmacotherapySeizure ManagementAnticonvulsant DrugsAnticonvulsant TreatmentLevetiracetam TherapyLevetiracetam TreatmentLevetiracetam-based TherapyNeonatal Anticonvulsant TherapyNeonatal Seizure TherapySeizures
AIM OF THE STUDY: The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first-line treatment of neonatal seizures. MATERIALS AND METHODS: This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses. RESULTS: All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regarding safety of LEV, no major side-effects were observed. CONCLUSIONS: To our knowledge, it is one of the few studies confirming the efficiency of LEV as first-line treatment in seizures of this age group. LEV was effective in resolving seizures and was safely administered in the current study.
19
Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use
Mark S. Scher, John Alvin, Lisa Gaus et al. · Pediatric Neurology · 2003 · 240 citations
Medicine, Neuroscience, Pharmacology +12
Levetiracetam: Safety and efficacy in neonatal seizures
Georgia Ramantani, Chrysanthy Ikonomidou, Beate Walter et al. · European Journal of Paediatric Neurology · 2010 · 152 citations
Medicine, Pediatrics, Pharmacology +12